Management of generalised anxiety disorder in adults: Summary of NICE guidance

National Collaborating Centre for Mental Health, Royal College of Psychiatrists, London, UK.
BMJ (online) (Impact Factor: 17.45). 01/2011; 342(jan26 1):c7460. DOI: 10.1136/bmj.c7460
Source: PubMed
1 Follower
16 Reads
    • "Participants with tricyclic's mainly complained about anticholinergic side effects, participants in the SSRI or SNRI groups reported sexual dysfunction, weight gain and increased nervousness as primary reasons to refuse further pharmacological treatment. However, as the acceptance profile of SSRIs/SNRIs is usually better and side effects are less severe, these drugs are primarily recommended as first line standard treatment of (Kapczinski, et al., 2003; Kendall, et al., 2011). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Five types of intervention may be of special relevance and in consequence have been included in treatments targeting generalized anxiety disorder (GAD) symptomology: metacognitive therapy targeting both negative and positive metacognitions concerning worrying; fear imagery exposure, based on the avoidance theory of worrying; interventions developed to increase tolerance of uncertainty; relaxation exercises; and finally, treatment modules focusing on negative problem orientation. This chapter first describes the diagnostic procedures most helpful for the preparation of treatment and then the treatment modules. All these modules have been included in manualized treatments, which have been evaluated with regard to their efficacy in a number of RCTs. The chapter presents an overview of the evidence for the efficacy of variations of this cognitive-behavioral treatment (CBT). Applied relaxation is one of the most regularly used components within standard CBTs for GAD. Besides cognitive-behavioral therapy and psychodynamic psychotherapy, pharmacotherapy offers another evidence-based treatment option for GAD.
    The Wiley Handbook of Anxiety Disorders, 04/2014: pages 1003-1037; , ISBN: 9781118775356
  • [Show abstract] [Hide abstract]
    ABSTRACT: I thought that the publication of the review on preventing exacerbations of chronic obstructive pulmonary disease (COPD) (from Drug and Therapeutics Bulletin; DTB) and the summary of National Institute for Health and Clinical Excellence guidance on the management of generalised anxiety disorder in adults …
    BMJ Clinical Research 12/2010; 342. DOI:10.1136/bmj.d995 · 14.09 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Major depressive disorder (MDD) has shown to cause high costs to society. Earlier research indicates that generalized anxiety disorder (GAD) also causes high costs, but only limited data is available in varying settings. Aims: To analyse the secondary care costs of GAD compared with those of MDD. Methods: Retrospective database analysis from Finnish Hospital Discharge Registers (FHDR). All GAD and MDD patients diagnosed between 1 January 2007 and 31 December 2007 in FHDR were recorded and individual-level secondary care costs during a 48-month follow-up period were measured. Results: The total mean cost of GAD with history of MDD or some other anxiety disorder was significantly higher than that of MDD with history of GAD or some other anxiety disorder during the 48-month follow-up period. The costs of pure GAD were comparable with those of pure MDD, but after adjusting for age and sex, the costs of pure MDD were higher than those of pure GAD. Conclusions: The economic burden of individual GAD patients is comparable with that of MDD patients in secondary care.
    Nordic journal of psychiatry 08/2013; 68(5). DOI:10.3109/08039488.2013.817605 · 1.34 Impact Factor
Show more


16 Reads
Available from